LUXFER HOLDINGS PLC 8-K

What Happened

• On July 26, 2026 Luxfer Holdings PLC entered into a Transaction Agreement with Double Eagle Acquisition Buyer, Inc., a holding company owned by funds managed by Wynnchurch Capital L.P., under which Buyer will acquire all issued ordinary shares of Luxfer for $17.37 in cash per share via a court‑sanctioned English law scheme of arrangement.
• The Luxfer board approved the Transaction Agreement, will seek Court directions and intends to recommend the transaction to shareholders, subject to the terms and conditions in the agreement. If completed, Luxfer’s ordinary shares will be delisted from the NYSE and deregistered under the U.S. Securities Exchange Act.
• The deal is subject to customary closing conditions (including shareholder approval, HSR and other antitrust/foreign investment clearances, Court sanction of the scheme) and an outside closing date of February 26, 2027.

Key Details

• Transaction Agreement signed: July 26, 2026; public announcements: July 27, 2026.
• Cash consideration: $17.37 per ordinary share.
• Termination fees: Company Termination Payment = $18,000,000; Buyer Termination Payment = $32,250,000.
• Financing: equity commitment from a Wynnchurch-managed fund and debt commitment from institutional lenders; the closing is not conditioned on financing.
• Treatment of equity awards: outstanding options, RSUs and PSUs will generally vest (per terms) and be cancelled for cash equal to the Consideration (with special rules for performance awards); options with exercise price above $17.37 will be cancelled for no consideration.
• Deadline: transaction must close by Feb 26, 2027 unless extended under the agreement.

Why It Matters

• For Luxfer shareholders: if the scheme is approved and closes, each ordinary share will be cashed out at $17.37 and public trading/listing will end — shareholders should expect a proxy statement with voting materials and timelines.
• The board recommends the deal, but completion depends on shareholder votes, UK court sanction and regulatory approvals; the agreement includes non‑solicitation protections and defined paths for competing bids (with potential break fees).
• Investors should review the forthcoming proxy materials and press releases for details on timing, voting, and how equity awards will be paid.